Published in Lancet on July 03, 1999
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol (2002) 2.18
Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol (2008) 1.96
Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol (2002) 1.94
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol (2002) 1.83
HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer (2001) 1.52
comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol (2005) 1.44
Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39
Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol (2002) 1.36
Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer (2007) 1.32
A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol (2005) 1.31
Acceptability of human papillomavirus self testing in female adolescents. Sex Transm Infect (2005) 1.24
International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol (2003) 1.23
Comparison of non-invasive sampling methods for detection of HPV in rural African women. Sex Transm Infect (2005) 1.22
Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer (2005) 1.22
Screening for cervical cancer: should we test for infection with high-risk HPV? CMAJ (2000) 1.21
Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in north India. J Clin Microbiol (2008) 1.19
Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology. J Mol Diagn (2005) 1.18
Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer (2001) 1.15
HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer (2001) 1.14
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol (2000) 1.14
High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol (2006) 1.11
Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18. Mol Pathol (2001) 1.11
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol (2006) 1.11
Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis (2009) 1.09
Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis (2011) 1.08
Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer (2004) 1.08
A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer (2000) 1.08
Correlates of IL-10 and IL-12 concentrations in cervical secretions. J Clin Immunol (2003) 1.06
A simplified and reliable HPV testing of archival Papanicolaou-stained cervical smears: application to cervical smears from cancer patients starting with cytologically normal smears. Br J Cancer (2000) 1.05
Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh. Jpn J Clin Oncol (2012) 1.01
Cervical cytology after 2000: where to go? J Clin Pathol (2000) 0.95
Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. J Clin Microbiol (2012) 0.93
Factors affecting the detection rate of human papillomavirus. Ann Fam Med (2004) 0.93
Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One (2011) 0.92
Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer (2010) 0.92
Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls. Mediators Inflamm (2007) 0.92
Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol (2006) 0.92
Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med (2012) 0.92
Treatment of the patients with abnormal cervical cytology: a "see-and-treat" versus three-step strategy. J Gynecol Oncol (2009) 0.91
Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol (2005) 0.90
High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum. Br J Cancer (2002) 0.90
Microbicides for HIV prevention. Indian J Med Res (2011) 0.90
Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage. Int J Cancer (2012) 0.90
Differential expression of ANXA6, HSP27, PRDX2, NCF2, and TPM4 during uterine cervix carcinogenesis: diagnostic and prognostic value. Br J Cancer (2010) 0.90
The human urine virome in association with urinary tract infections. Front Microbiol (2015) 0.90
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Management of low-grade squamous intraepithelial lesions of the uterine cervix. Br J Cancer (2004) 0.89
A novel strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction. Am J Pathol (2001) 0.88
Treatability by cryotherapy in a screen-and-treat strategy. J Low Genit Tract Dis (2009) 0.88
Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. BMC Infect Dis (2010) 0.86
Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol (2001) 0.86
Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol (2003) 0.86
Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer (2011) 0.85
Mild obesity, physical activity, calorie intake, and the risks of cervical intraepithelial neoplasia and cervical cancer. PLoS One (2013) 0.85
Human papillomavirus testing in cervical cancer screening. Br J Cancer (2005) 0.84
Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol (2009) 0.83
Cumulative Impact of HIV and Multiple Concurrent Human Papillomavirus Infections on the Risk of Cervical Dysplasia. Adv Virol (2016) 0.83
Evolution of human papillomavirus carcinogenicity. Adv Virus Res (2010) 0.83
Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br J Cancer (2000) 0.83
Screening of uterine cervical cancer in low-resource settings. J Gynecol Oncol (2012) 0.82
Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer (2012) 0.81
Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. Cancer Med (2015) 0.81
Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis (2014) 0.80
Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopical atypia. J Clin Microbiol (2000) 0.79
Relationship between plasma glucose levels and malignant uterine cervical neoplasias. Clin Med Insights Oncol (2011) 0.79
Detection of human papillomavirus in chronic cervicitis, cervical adenocarcinoma, intraepithelial neoplasia and squamus cell carcinoma. Jundishapur J Microbiol (2014) 0.79
Prevalence of high-risk human papillomavirus and abnormal pap smears in female sex workers compared to the general population in Antwerp, Belgium. BMC Public Health (2016) 0.78
Do clinical data and human papilloma virus genotype influence spontaneous regression in grade I cervical intraepithelial neoplasia? J Turk Ger Gynecol Assoc (2017) 0.78
Pharyngeal squamous cell papilloma in adult Japanese: comparison with laryngeal papilloma in clinical manifestations and HPV infection. Eur Arch Otorhinolaryngol (2012) 0.77
Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother (2015) 0.76
Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing. Br J Cancer (2002) 0.76
High prevalence of human papillomavirus infections in urine samples from human immunodeficiency virus-infected men. J Clin Microbiol (2005) 0.76
[Risk-adapted multimodal laboratory cervical screening---Pap test of the future?]. Pathologe (2007) 0.76
The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinoma. Clin Med Insights Oncol (2011) 0.76
CXCL12 rs266085 and TNF-α rs1799724 polymorphisms and susceptibility to cervical cancer in a Chinese population. Int J Clin Exp Pathol (2015) 0.75
3q26 amplification is an effective negative triage test for LSIL: a historical prospective study. PLoS One (2012) 0.75
Vaccines against human papilloma virus and cervical cancer: an overview. Indian J Community Med (2008) 0.75
High risk human papillomavirus persistence among HIV-infected young women in South Africa. Int J Infect Dis (2015) 0.75
Dried cervical spots for human papillomaviruses identification. J Med Virol (2013) 0.75
SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China. Int J Gynecol Cancer (2010) 0.75
Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia. Int J Cancer (2016) 0.75
Prevalence of pks-positive Escherichia coli in Japanese patients with or without colorectal cancer. Gut Pathog (2017) 0.75
Subsequent risks for cervical precancer and cancer in women with low-grade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy: results from a multicenter, prospective, cohort study. Int J Clin Oncol (2011) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol (1995) 10.07
A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09
A new method for the isolation of herpes simplex virus type 2 DNA. Virology (1976) 4.61
The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol (1990) 4.09
Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer (1995) 3.29
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol (1990) 3.21
Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol (1995) 3.20
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer (1996) 2.91
Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer (2000) 2.86
Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect (2001) 2.85
The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78
General primer-mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas. Int J Cancer (1990) 2.69
Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer (1993) 2.60
Direct detection and genotyping of Chlamydia trachomatis in cervical scrapes by using polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol (1993) 2.59
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood (2001) 2.54
Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol (1998) 2.47
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43
Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut (1980) 2.24
Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer (1994) 2.23
Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23
RNA amplification by nucleic acid sequence-based amplification with an internal standard enables reliable detection of Chlamydia trachomatis in cervical scrapings and urine samples. J Clin Microbiol (1996) 2.22
The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol (2001) 2.21
Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst (1998) 2.19
Campylobacter colitis: histological immunohistochemical and ultrastructural findings. Gut (1985) 2.15
PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer (1996) 2.13
Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev (1997) 2.12
Expression of the nuclear oncogene p53 in colon tumours. J Pathol (1989) 2.05
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer (1995) 2.00
Improved PCR sensitivity for direct genotyping of Chlamydia trachomatis serovars by using a nested PCR. J Clin Microbiol (1994) 1.97
Use of anticontamination primers in the polymerase chain reaction for the detection of human papilloma virus genotypes in cervical scrapes and biopsies. J Med Virol (1989) 1.95
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94
Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem (1998) 1.90
Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer (1991) 1.89
High endothelial differentiation in human lymphoid and inflammatory tissues defined by monoclonal antibody HECA-452. Am J Pathol (1988) 1.86
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol (2000) 1.83
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer (2001) 1.82
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79
In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies. J Rheumatol (1982) 1.78
Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer (1988) 1.78
Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol (1994) 1.76
PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol (2000) 1.73
Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res (1994) 1.73
Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res (2000) 1.72
The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer (1998) 1.69
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol (2000) 1.69
Chlamydia trachomatis and ectopic pregnancy: retrospective analysis of salpingectomy specimens, endometrial biopsies, and cervical smears. J Clin Pathol (1995) 1.69